Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses (Q36626247)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 2006

Language	Label	Description	Also known as
English	Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses	scientific article published on November 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

0 references

author name string

Martin S Turner

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Duncan W Stewart

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

language of work or name

0 references

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

6 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

20-37

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Factors influencing relapse in the long-term course of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Clozapine maintenance therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Tolerability of atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

An economic review of compliance with medication therapy in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Cost of relapse in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Neuroleptics and the Natural Course of Schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Guidelines for depot antipsychotic treatment in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071243

21 January 2018

Identifiers

10.1177/1359786806071243

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

release_tel3ofh7pnelvd467vhdzw7v24

1 reference

https://api.fatcat.wiki/v0/release/tel3ofh7pnelvd467vhdzw7v24

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36626247&oldid=1838764207"